Skip to main content
. Author manuscript; available in PMC: 2015 Apr 15.
Published in final edited form as: Cancer Res. 2014 Mar 31;74(8):2295–2305. doi: 10.1158/0008-5472.CAN-13-1803

Figure 4. IGF-I stimulated xC− transporter function in ER positive breast cancer cells.

Figure 4

Cells were pretreated with SASP (0.1 mM) for 48 h, BSO (0.05 or 0.1 mM) for 24 h. (A) MCF-7, T47D, and MDA-MB-231 cells were grown in SFM for 24 h then treated with indicated treatments with or without IGF-I (5nM) for another 24 h. Culture media glutamic acid levels were analyzed and readings were normalized to MTT reading. (B) MCF-7 and T47D cells were grown in SFM for 24 h then treated with indicated treatments with or without IGF-I (5nM) for another 24 h. Intracellular reduced GSH concentration was determined as described. Data are mean ± SEM; all results are representative of three independent replicates.